Journal
VACCINE
Volume 23, Issue 19, Pages 2424-2429Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2004.11.024
Keywords
hepatitis A vaccine; randomized trial; immunogenicity
Categories
Ask authors/readers for more resources
The interchangeability of virosomal (Epaxal (R)) and aluminum-adsorbed (Havrix 1440 (R)) hepatitis A virus (HAV) vaccines was studied in 111 healthy adults who were vaccinated in a randomized, single-blind, crossover clinical trial. Anti-HAV antibody titers were measured at days 0 (first dose), 14, and 28, and months 3, 6, 12 (second dose), 13, 24, 36, 48, 60 and 72. Most subjects (> 95%) had sero-converted 14 days after the first dose of either vaccine. The second dose with either vaccine induced a high antibody response in all vaccines, irrespective of the type of vaccine administered as the first dose. Although both vaccines were well tolerated, the incidence of local adverse events (in particular pain) was significantly lower in subjects receiving the virosomal vaccine. Six-year follow-up data did not reveal any significant differences between the vaccination groups. (c) 2004 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available